Scarica l'app Stockscreener
10.17
1.90%
0.19
Pre-mercato:
10.17
Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie
(CRBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals (NASDAQ: CRBP) seeks approval to expand equity plan and confirm pay policies - stocktitan.net
Corbus Pharmaceuticals Holdings, Inc. advances next-gen ADC targeting Nectin-4 in aggressive cancers - Traders Union
Mizuho raises Corbus Pharmaceuticals stock price target on updated CRB-701 assumptions - Investing.com Canada
CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
CRBP PE Ratio & Valuation, Is CRBP Overvalued - Intellectia AI
CEO Change: What is the cash position of Corbus Pharmaceuticals Holdings Inc2026 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Published on: 2026-03-31 10:02:36 - baoquankhu1.vn
Aug Shorts: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveWeekly Trend Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
STU:3371 PB Ratio: 1.04 — 73% Below Median - gurufocus.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP SEC FilingsCorbus Pharmaceu 10-K, 10-Q, 8-K Forms - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf to sell equity, debt - Stock Titan
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Repeat Insider Selling Not A Positive Indicator - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit - Traders Union
[EFFECT] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
How (CRBP) Movements Inform Risk Allocation Models - Stock Traders Daily
If You Invested $1,000 in Corbus Pharmaceu (CRBP) - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Prosight Management LP Decreases Stock Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
Dermatomyositis Market: Strong Pharma Growth Forecast Through - openpr.com
HC Wainwright Issues Negative Forecast for CRBP Earnings - MarketBeat
Trading Systems Reacting to (CRBP) Volatility - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf registration - Stock Titan
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance
Research Analysts Offer Predictions for CRBP FY2030 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for Corbus Pharmaceuticals (CRBP) to $57 | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. 2024 Annual Report: Pipeline, Intellectual Property, Regulatory Overview, and Business Strategy - Minichart
Corbus Pharmaceuticals (CRBP) Beats Q4 EPS Estimates - GuruFocus
Corbus Pharmaceuticals (NASDAQ: CRBP) details 2025 losses, cash and key trial data - Stock Titan
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results, Highlights Promising CRB-701 and CRB-913 Clinical Updates and Extends Cash Runway Into 2028 - Minichart
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q4 and annual financial update released, Corbus Pharmaceuticals Holdings, Inc. outlines - Traders Union
Corbus Pharmaceuticals 2025 Financials: Q4 Loss of $20.6M, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress - TipRanks
Corbus Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Corbus Pharmaceuticals (NASDAQ:CRBP) Releases Quarterly Earnings Results - MarketBeat
Corbus Pharmaceuticals (CRBP) Eyes Breakthroughs with CRB-701 an - gurufocus.com
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - Bitget
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):